Interest of contrast-enhanced sonography to identify focal nodular hyperplasia with sinusoidal dilatation  by Alberti, N. et al.
Diagnostic and Interventional Imaging (2014) 95, 77—83
SHORT ORIGINAL ARTICLE / Gastrointestinal imaging
Interest  of  contrast-enhanced  sonography
to identify  focal  nodular  hyperplasia  with
sinusoidal dilatation
N.  Alberti a,∗,  N.  Frulioa,  P.  Bioulac-Sageb,c,
H. Laumoniera,  C.  Balabaudb,  J.-T.  Pereza,
F.R. Teixeira  Jr.d,  N.  Harbonniere,  H.  Trillauda
a Service  d’imagerie  diagnostique  et  interventionnelle,  hôpital  Saint-André,
CHU  de  Bordeaux,  1,  rue  Jean-Burguet,  33000  Bordeaux,  France
b Inserm  U1053,  université  Bordeaux  Segalen,  33076  Bordeaux,  France
c Pathology  Department,  Hôpital  Pellegrin,  CHU  Bordeaux,  place  Amélie-Raba-Léon,
Bordeaux,  France
d Radiology  Department,  Institut  Bergonié,  Regional  Cancer  Center,  33076  Bordeaux  cedex,
France
e Service  d’imagerie,  Hôpital  d’Instruction  des  Armées  Robert  Picqué,  351,  route  de  Toulouse,












Background  and  aims:  Focal  nodular  hyperplasia  with  major  sinusoidal  dilatation  (FNH-sd)  is  a
misleading  entity,  with  some  features  resembling  inﬂammatory  hepatocellular  adenoma  (HCA).
We  aimed  to  assess  the  performance  of  contrast-enhanced  ultrasound  (CEUS)  for  the  diagnosis
of  FNH-sd.
Methods:  Four  histologically  proven  FNH-sd  nodules  in  four  patients  were  investigated  with
both  MRI  and  CEUS  imaging.  Sinusoidal  dilatation  was  focally  visible  in  all  cases  in  histology.
Results: In  MRI,  in  all  the  four  cases,  lesions  were  hypervascular  in  arterial  phase,  with
high  intensity  in  T2-weighted  sequence  imaging  and  persistent  enhancement  in  the  delayed
gadolinium-enhanced  phase.  These  MRI  features  were  more  indicative  of  HCA  than  FNH.  On  the
other  hand,  CEUS  showed  a  very  speciﬁc  centrifugal  ﬁlling  followed  by  a  strong,  homogeneous
enhancement  of  the  whole  lesion.
Conclusion:  CEUS  seems  to  be  an  essential  step  for  the  diagnosis  of  non-typical  FNH,  such
as  FNH-sd.  This  small  series  hig
diagnosis  of  atypical  focal  liver  l
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NHa  focal  nodular  hyperplasia
CA hepatocellular  adenoma
RI magnetic  resonance  imaging
NH-sd focal  nodular  hyperplasia  with  sinusoidal  dilatation
FNH telangiectasic  focal  nodular  hyperplasia
S glutamine  synthetase
FBAP liver  fatty  acid-binding  protein
RP C-reactive  protein
AA serum  amyloid  A
NF1   Hepatocyte  nuclear  factor-1  alpha
S ultrasound
EUS  contrast-enhanced  ultrasound
ASLD American  Association  for  the  Study  of  Liver  Diseases
K7 cytokeratins  7
ntroduction
ajority  of  focal  liver  lesions  are  benign  in  non-cirrhotic
iver. Focal  nodular  hyperplasia  (FNH)  is  the  second  most
ommon benign  liver  tumor  after  hemangioma  [1].  The
revalence is  estimated  at  0.9%  of  the  general  population
2]. Although  FNH  may  affect  both  sexes  of  all  ages,  it  is
ore common  in  females  (80%—95%)  in  their  third  or  fourth
ecade of  life  [2].  FNH  is  often  solitary  but  may  be  multiple
n approximately  20%  of  cases.  The  pathogenesis  of  FNH  is
ot well  understood,  but  it  is  thought  to  be  a  non-speciﬁc
esponse to  locally  increased  blood  ﬂow.  This  hypothesis  is
trengthened by  the  fact  that  FNH  can  also  be  associated
ith vascular  abnormalities  as  hepatic  hemangiomas  [3].  In
995, the  International  Working  Party  classiﬁed  FNH  with
ther regenerative  lesions,  in  contrast  to  adenoma  (HCA),
hich is  known  as  a  neoplastic  lesion  [4].
FNH  is  usually  asymptomatic,  and  most  cases  are  discov-
red incidentally  on  abdominal  imaging.  Clinical  symptoms
ue to  mass  effect  are  infrequent.  These  lesions  must  still
e correctly  diagnosed  because  surgical  resection  is  limited
o symptomatic  FNH,  while  the  others  are  left  untreated.
FNH  in  its  typical  form  is  an  easy  diagnosis  with  cross-
ectional contrast-enhanced  imaging.  Thus,  the  imaging
eatures of  FNH  include  homogenous  lesions,  signiﬁcant
nhancement on  the  arterial  phase  with  a  lack  of  washout
uring the  portal  venous  and  delayed  phases,  peripheral  lob-
lation and  the  presence  of  a  central  scar.  Based  on  these
riteria, CT  and/or  MRI  have  a  sensitivity  of  70%  and  a  speci-
city of  100%  for  the  diagnosis  of  FNH.
However,  in  daily  practice,  there  are  still  some  difﬁcul-
ies concerning  less  typical  forms,  such  as  pre/incomplete
NH, absence  of  central  scar,  presence  of  steatosis  and
inusoidal dilatation.  The  so-called  ‘‘telangiectasic  FNH’’
TFNH) was  shown  to  be,  at  the  histological  level,  closer
o the  family  of  hepatocellular  adenomas  (HCA)  than  to  FNH
tself [5,6].  Subsequently,  it  was  shown  that  most  of  the
o-called TFNH  were  inﬂammatory  HCA  [7].  More  recently,
he distinction  between  FNH  and  other  lesions,  like  inﬂam-
atory HCA,  has  been  largely  solved  with  the  progresses
f molecular  biology  and  its  application  in  immunohisto-
hemistry. Indeed,  glutamine  synthetase  (GS),  markedly
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as  used  as  a  useful  immunohistological  marker  to  differen-
iate FNH  from  HCA  [8].  Moreover,  FNH  does  not  express
arkers of  HCA  subtypes:  particularly  C-reactive  protein
CRP) and  serum  amyloid  (SAA)  are  negative,  whereas  they
re overexpressed  in  inﬂammatory  HCA.  In  addition,  liver
atty acid-binding  protein  (LFABP)  is  normally  expressed  in
NH contrary  to  its  absence  in  hepatocyte  nuclear  factor-1
lpha (HNF1)  mutated  adenoma  [7—9].
In  this  short  article,  we  report  four  cases  of  histologically
onﬁrmed FNH  with  sinusoidal  dilatation  (FNH-sd).  MRI  and
ontrast-enhanced ultrasound  (CEUS)  data  were  retrospec-
ively analysed  to  determine  speciﬁc  semiological  pattern
f these  particular  FNH  type.
ethods
his  retrospective  and  monocentric  study  had  the  approval
f our  Research  Ethics  Board  for  chart  review.
We  identiﬁed  four  patients  with  FNH-sd  from  December
008 to  November  2011  in  the  database  of  our  pathol-
gy department.  Histological,  medical  (including  blood  liver
ests) and  radiological  data  were  collected  and  analyzed.
istological analysis
ercutaneous  needle  biopsies  were  performed  under
ltrasonographic guidance  using  a  16—18  Gauge  needle,
ccording to  the  recommendations  of  the  American  Asso-
iation for  the  Study  of  Liver  Diseases  (AASLD).  At  least  two
ores of  liver  tissue  were  obtained  per  patient.
The  biopsy  specimens  were  processed  and  parafﬁn  sec-
ions were  stained  with  H&E,  Masson’s  trichrome,  Perls.
dditional immunostaining  was  performed,  such  as  cytok-
ratins (K)  7  and  19,  as  well  as  glutamine  synthetase  (GS),
erum amyloid  A  (SAA),  C-reactive  protein  (CRP)  and  -
atenin.
RI
RI  was  performed  on  a 1.5  T  MRI  system  (Achieva,  Phillips
edical System,  Best,  The  Netherlands),  in  our  radiol-
gy department.  For  all  MRI  examination,  the  following
equences were  acquired  and  analysed:  axial  in-phase
nd out-of-phase  chemical-shift  GRE  T1-weighted  (T1  W)
mages (repetition  time/echo  time,  208/2.3  and  4.6  msec;
ip angle,  80◦;  ﬁeld  of  view,  430  mm;  matrix,  292  ×  178;
umber of  sections,  30;  section  thickness,  5.4  mm;  two
ignals acquired);  a  respiratory-triggered,  fat-suppressed,
2-weighted (T2  W)  fast  spin-echo  pulse  sequence  (repeti-
ion time/echo  time,  1,287/70  msec;  ﬂip  angle,  90◦;  ﬁeld
f view,  450  mm;  matrix,  308  ×  156;  number  of  sections,
0; section  thickness,  5  mm;  one  signal  acquired);  a  T2  W
ast spin-echo  pulse  sequence  (repetition  time/echo  time,
31/60 msec;  ﬂip  angle,  90◦;  ﬁeld  of  view,  395  mm;  matrix,
56 ×  136;  number  of  sections,  25;  section  thickness,
 mm;  one  signal  acquired);  and  fat-suppressed  dynamic
adolinium-enhanced T1  W  gradient  echo  sequences  dur-
ng the  arterial  phase,  late  arterial  phase,  portal  venous
hase, and  delayed  phase,  with  manual  administration  of
adolinium-based contrast  medium  (repetition  time/echo
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matrix,  192  ×  138;  number  of  sections,  37;  section  thick-
ness, 5  mm;  one  signal  acquired).  The  contrast  agent  used
in all  cases  was  Multihance®  (Gadobenatediméglubine,
Bracco,  Milan,  Italy).  Additional  hepatobiliary  phase  images
were obtained  at  least  60  min  after  injection  in  only  one
case.
US and CEUS
All  contrast-enhanced  ultrasound  were  also  performed  in
the radiology  department,  in  the  same  machine  (Acuson
Sequoia®,  Siemens  Medical  System,  Erlangen,  Germany),  by
a radiologist  with  at  least  5  years  of  experience  in  CEUS.
Baseline gray-scale  sonography  was  performed  to  iden-
tify each  hepatic  lesion,  after  which  low  mechanical-index
(0.07—0.2) contrast-enhanced  sonography  was  performed
after a  contrast  agent  bolus  injection  of  0.1—0.3  mL.
Injections were  repeated  two  times.  The  contrast  agent
(Sonovue®,  Bracco,  Milan,  Italy)  was  injected  through  a
peripheral venous  line  by  one  of  the  department  nurses.
Imaging evaluation
All  MRI  and  contrast-enhanced  ultrasound  data  were
reviewed by  three  abdominal  radiologists  (H.L.,  H.T.,  N.F.)
and discussed  until  there  was  a  consensus.  The  three  radio-
logists were  blinded  to  the  histological  diagnoses.  Some
features were  searched  both  in  MRI  and  in  CEUS.  Others,  con-
sidered to  be  speciﬁc  to  each  of  the  methods,  were  searched
in only  one  of  the  methods.
For both  MRI  and  CEUS,  we  have  analyzed  the  number
of lesions,  its  location  (according  to  Couinaud’s  numbering
system), maximum  diameter,  as  well  as  morphologic  aspects
such as  limits  (clearly  or  poorly  delimited),  borders  (regular
or lobulated)  and  appearance  (homogeneous  or  heteroge-
neous).
For MRI,  the  following  criteria  were  analysed:  homo-
geneous or  heterogeneous  appearance  of  the  lesion  on
each sequence;  presence  of  fat  deposition  within  the  lesion
(absence, focal  or  diffuse  distribution  in  the  lesion);  pres-
ence of  haemorrhagic  and/or  necrotic  components;  signal
intensity on  T1  W  and  T2  W  imaging,  type  of  enhancement
at the  arterial  phase  (homogenous-heterogenous),  signal
intensity of  the  lesion  at  the  portal  and  delayed  phase
and when  possible  at  the  very  delayed  phase,  so-called
‘‘hepatobiliary phase’’,  presence  of  central  scar,  and  accu-
mulation of  gadolinium  chelates  within  the  central  area  on
delayed contrast-enhanced  T1-weighted  sequences.  For  the
surrounding liver  parenchyma:  morphological  feature  (dys-
morphy), and  steatosis  (homogenous/heterogenous),  were
collected.
For  CEUS,  the  readers  were  asked  to  search  and  describe
the behavior  of  the  lesion  during  arterial,  venous  and  late-
venous phases  (hyper-,  iso-or  hypovascular),  the  pattern
of enhancement  (centrifugal,  centripetal  or  mixed),  the
presence of  peripheral  linear  vascularities,  a  transient  unen-
hanced zone  and  of  a  rim  of  persistent  enhancement  in  the
late venous  phase.  Central  stellate  arteries  were  deﬁned  by
the presence  of  enhancing  central  arteries  with  a  spoked-
wheel or  star  like  morphology.  A  central  scar  was  deﬁned  as
a central  stellate  hypoechoic  linear  or  plicated  area  without







ndications  of  liver  biopsies  were  neoplastic  context  for  one
atient (case  1)  and  atypical  aspect  on  MRI  in  all  patients.
In  histology,  all  the  cases  corresponded  to  a benign  pro-
iferation of  hepatocytes  without  any  cytological  atypia;
brous bands  containing  thick  arteries  were  focally  visible,
ith a  few  inﬂammatory  cells  associated.  In  one  case,  the
uctular reaction  was  obvious;  in  two  it  was  mild,  underlined
y K7  immunostaining.  In  all  cases,  sinusoidal  dilatation  was
ocally visible  separating  thin  strands  of  hepatocytes.
In  addition,  GS  immunostaining  showed  large  positive
epatocytes areas  (Fig.  1),  often  centered  by  veins,  far  from
brous bands;  there  was  no  aberrant  staining  of  -catenin;
AA and  CRP  immunostainings  were  negative.
linical ﬁndings
he  four  patients  included  in  the  study  were  female  and
ere from  32  to  46  years  old  with  a  mean  age  of  39
± 7  years).  Two  of  them  (cases  2,  4)  had  no  speciﬁc  medi-
al history.  The  lesions  were  discovered  incidentally  on
ltrasound examinations  performed  for  assessment  of  pelvic
ain. The  two  remaining  patients  (cases  1  and  3)  had  a  spe-
iﬁc clinical  setting:  one  patient  (case  3)  was  followed  for
cquired immunodeﬁciency  associated  with  HIV  and  her  liver
esion was  discovered  during  a  CT  scan  performed  to  explore
 chronic  cough;  the  other  one  (case  one1)  was  followed
or melanoma.  In  these  two  cases,  the  lesions  were,  on  CT
mages, hypodense,  not  well  deﬁned  and  non-speciﬁc.  The
ontrast enhancement  of  lesions  on  CT  scan  was  not  stud-
ed. Transaminases  were  elevated  (3  times  the  normal  rate)
n one  patient  (case  1).
RI ﬁndings
he  morphological  characteristics  of  the  nodules  in  MRI
ere a  mean  size  of  23  mm  (14  to  43  mm),  hyperintensity
n T2WI  and  hypointensity  on  T1.  All  lesions  were  homo-
eneous both  on  T1  and  T2-weighted  sequences  and  no
ignal dropout  on  chemical-shift  sequences  was  found.  No
entral scar  was  found.  The  lesions  were  located  in  seg-
ent VI  (3  out  of  4  lesions)  and  in  segment  V  (1  out  of
). Hemorrhagic,  necrotic,  or  fat  components  within  the
esions were  not  identiﬁed  in  our  cases.  No  liver  dysmor-
hia was  found.  Steatosis  in  the  healthy  parts  of  the  liver
as observed  in  only  one  case  (case  3).  All  lesions  showed  a
trong arterial  enhancement  and  had  a  persistent  enhance-
ent in  the  delayed  phase.  No  wash  out  was  found  in  any
esion. In  the  hepatobiliary  phase  images,  obtained  in  only
ne patient,  the  nodule  was  hypointense  to  the  surrounding
iver parenchyma  (Figs.  2  and  3).
S and CEUS ﬁndings
n  non-enhanced  B-mode  ultrasound,  the  echogenicity  was
ighly variable:  mixed  (1  nodule),  isoechogenic  (1  nodule),
yperechogenic (1  nodule)  and  hypoechogenic  (1  nodule).
 hyperechogenic  ring  was  visualized  in  one  lesion  and  a
ypoechogenic ring  in  another  one.  During  color  and  spectral
80  N.  Alberti  et  al.








ahin strands of hepatocytes (asterisk). GS immunostaining showed 
brous bands (asterisk). Case 1.oppler  analysis,  a  central  arterial  pedicle  with  low  resis-
ance index  was  visualized  in  only  one  lesion.
After  the  injection  of  contrast,  all  the  lesions  showed





igure 2. MRI. Segment 6 lesion with (a) an intense hypersignal on T2
fter gadolinium administration and (c) persistent enhancement at dela
fter injection) (d), the nodule was hypointense (arrow). Case 1.rge positive hepatocytes areas, often centered by veins, far fromentrifugal  ﬁlling  in  all  cases,  as  well  as  the  presence  of
tellate arteries  and  ‘‘spoke  wheel’’  signs  (100%).  All  lesions
howed sustained  portal  venous  phase  enhancement  for
elayed phase  (5  minutes)  (Figs.  4  and  5).
 W fast spin-echo pulse sequence, (b) strong arterial enhancement
yed phase (5mn) (arrows). In the hepatobiliary phase images (1H





nFigure 3. MRI. Segment 5 lesion with (a) an intense hypersignal o
after gadolinium administration and (c) persistent enhancement at
Discussion
It  is  of  major  clinical  importance  to  differentiate  FNH  from
HCA. Once  the  diagnosis  of  FNH  is  established,  neither  treat-
ment nor  follow-up  are  necessary  (‘‘do  not  touch  lesion’’).
On the  opposite,  HCA  requires  follow-up  if  smaller  and  may
i
t
Figure 4. CEUS. The lesion shows (a) hypervascularity in the arterial ph
by (b, c) homogeneous enhancement of mass. Case 1. W fast spin-echo pulse sequence, (b) strong arterial enhancement
ed phase (10 mn) (arrows). Case 2.
ndicate  surgery  if  its  size  exceeds  5  cm,  in  order  to  avoid
he risk  of  bleeding  and  malignant  transformation.  Unfortu-
ately, the  differential  diagnosis  between  FNH  and  HCA  by
maging techniques  is  far  from  easy  in  10—20%  of  cases.
Among  the  difﬁculties  to  identify  FNH,  there  could  be
he presence  of  sinusoidal  dilatation.  Sinusoidal  dilatation
ase with centrifugal ﬁlling and spoke wheel sign (arrow), following












































wigure 5. CEUS. The lesion (arrow), shows (a, b, c) hypervasc
omogeneous enhancement of mass. Case 2.
s  one  of  the  major  histopathological  criteria,  in  addition  to
nﬂammation, to  identify  inﬂammatory  HCA.  To  what  extent
he entity  TFNH,  described  in  1989  by  Wanless  [10]  that  does
ot belong  to  inﬂammatory  HCA,  exists  and  is  similar  to  the
erm FNH  with  sinusoidal  dilatation  is  unknown.  Fortunately,
owadays the  distinction  between  FNH  and  HCA  has  been
argely solved  with  the  progress  made  in  the  ﬁeld  of  molec-
lar biology  and  its  applications  in  immunohistochemistry.
ndeed, FNH  expresses  a  very  characteristic  GS  immuno-
taining [7]  and  does  not  express  markers  of  HCA  subtypes
9], especially  CRP  and  SAA  are  negative,  whereas  they  are
verexpressed in  inﬂammatory  HCA  and  there  is  no  aberrant
-catenin positive  nuclei,  contrary  to  -catenin  activated
CA. In  addition,  liver  fatty  acid-binding  protein  (LFABP)  is
ormally expressed  contrary  to  lack  in  HNF1  mutated  ade-
oma. These  differences  apply  to  surgical  specimen  as  well
s core-biopsies  [11].
Now,  it  is  clear  that  FNH-sd  does  exist,  and  an  observation
f this  particular  type  of  FNH  was  already  made  previously
12]. Despite  this  misleading  feature,  the  diagnosis  can  be
ade with  appropriate  imaging  technique.
The  important  ﬁnding  is  that  CEUS  is  an  essential  step  to
orrectly identify  FNH-sd.  This  is  due  most  probably  to  the
reater temporal  resolution  of  CEUS  than  MRI,  which  shows
entrifugal ﬁllings,  very  speciﬁc  of  FNH.
o
t
lty in the arterial phase with centrifugal ﬁlling following by (d)
It is  often  difﬁcult  to  distinguish  FNH-sd  from  inﬂam-
atory HCA  in  MRI.  The  presentation  of  the  lesions  is
ften almost  identical  and  very  atypical  for  FNH,  since
here is  absence  of  central  scar,  hyperintensity  on  T2WI
ignal, hypointensity  on  TIWI  and  persistent  enhancement
t the  delayed  phase  without  any  wash  out.  We  think
hat these  abnormalities  of  signal  could  be  explained  by
he sinusoidal  dilatation,  a common  feature  in  these  two
ntities. Other  signs  may  be  helpful  to  distinguish  these
ntities in  MRI.  Thus,  the  classic  ‘‘Atoll  sign’’,  character-
zed by  a hyperintense  signal  band  in  the  periphery  of
he lesion  (like  an  atoll)  and  isointensity  of  the  center  of
he lesion  with  respect  to  the  surrounding  liver  (like  the
urrounding sea)  on  T2-weighted  images,  is  very  speciﬁc
f inﬂammatory  HCA  Unfortunately,  this  sign  is  inconstant
present in  only  43%  of  inﬂammatory  HCA  in  a  previous
tudy [13]).
On the  opposite,  on  CEUS  the  lesions  were  hypervascular
ith radial  vascular  architecture,  a  feature  characteristic
f FNH  lesions,  suggesting  that  the  kinetics  of  enhancement
as more  important  than  the  morphological  features.
However,  in  our  study,  the  size  of  the  lesions  was  small
r intermidate  and  CEUS  could  be  limited  to  appreciate








[Diagnosis  of  focal  nodular  hyperplasia  with  sinusoidal  dilata
In  these  cases,  the  use  of  liver-speciﬁc  MRI  con-
trast agents,  such  as  Multihance® (Gadobenatedimeglubine,
Bracco,  Milan,  Italy)  or  Primovist® (Gadoxetic  acid,  Bayer
Healthcare, Germany),  may  help  to  differenciate  these
two entities  by  showing  the  biliary  excretion  product  in
FNH according  to  Grazioli  et  al.  [14].  Indeed,  FHNs  always
show bile  ductular  proliferation,  whereas  HCAs  do  not.  In
our series,  only  one  patient  was  evaluated  for  hepatobili-
ary enhancement  patterns  and  categorized  as  hypointense.
Zech et  al.  reported  that  no  enhancement  occurred  during
the hepatobiliary  phase  in  10—12%  of  FNH  [15].  In  our  case,
we thought  that  sinusoidal  dilatation  could  be  the  cause  of
the non-enhancement  due  to  the  rare  (but  present)  ductules
in this  type  of  lesion,  but  it  is  difﬁcult  to  afﬁrm.
Conclusion
In  this  small  series,  we  have  shown  four  cases  of  FNH-sd  in
which the  diagnosis  was  equivocal  on  MRI  and  was  strongly
suggested on  CEUS.  It  is  now  clear  that  FNH-sd  does  exist  and
despite its  misleading  features,  the  diagnosis  can  be  made
with appropriate  imaging  techniques.  CEUS  is  an  essential
step to  correctly  identify  FNH-sd,  which  is  most  probably
related to  its  greater  temporal  resolution  when  compared  to
MRI, leading  to  a  better  identiﬁcation  of  centrifugal  ﬁllings
and, therefore,  the  diagnosis  of  FNH.  Thus,  this  small  series
highlights the  interest  of  performing  both  CEUS  and  MRI  for
the diagnosis  of  atypical  focal  liver  lesions,  such  as  FNH-sd.
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